Bausch Health Companies Inc. (BHC)

NYSE: BHC · Real-Time Price · USD
6.48
-0.27 (-4.00%)
At close: Mar 28, 2025, 4:00 PM
6.49
+0.01 (0.15%)
After-hours: Mar 28, 2025, 7:58 PM EDT
-4.00%
Market Cap 2.38B
Revenue (ttm) 9.63B
Net Income (ttm) -46.00M
Shares Out 367.93M
EPS (ttm) -0.13
PE Ratio n/a
Forward PE 1.43
Dividend n/a
Ex-Dividend Date n/a
Volume 1,357,833
Open 6.71
Previous Close 6.75
Day's Range 6.46 - 6.74
52-Week Range 3.96 - 11.46
Beta 0.60
Analysts Hold
Price Target 7.20 (+11.11%)
Earnings Date Apr 30, 2025

About BHC

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The Intern... [Read more]

Sector Healthcare
CEO Thomas Appio
Employees 20,700
Stock Exchange NYSE
Ticker Symbol BHC
Full Company Profile

Financial Performance

In 2024, Bausch Health Companies's revenue was $9.63 billion, an increase of 9.91% compared to the previous year's $8.76 billion. Losses were -$46.00 million, -92.23% less than in 2023.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for BHC stock is "Hold." The 12-month stock price forecast is $7.2, which is an increase of 11.11% from the latest price.

Price Target
$7.2
(11.11% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Bausch + Lomb recalls some of its implantable eye lenses

Bausch + Lomb said on Thursday it will recall some of its implantable eye lenses after receiving reports of complications, the cause of which could not immediately be known.

1 day ago - Reuters

Bausch + Lomb Recalls EnVista Intraocular Lenses

The Canadian eyecare company said Thursday that it has made a voluntary recall of its intraocular lenses on its enVista platform.

1 day ago - Market Watch

Bausch Health to Announce First Quarter Results on April 30

LAVAL, QC / ACCESS Newswire / March 27, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter financial results after market close on Wednesday, April 30, 2025. Bausch Hea...

1 day ago - Accesswire

Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced a voluntary re...

1 day ago - Business Wire

Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 50 points on Wednesday.

Other symbols: CHWY
2 days ago - Benzinga

Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes

LAVAL, QC / ACCESS Newswire / March 25, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has priced its previously announced offering ...

3 days ago - Accesswire

Bausch Health Announces Conditional Redemption of Senior Notes

LAVAL, QC / ACCESS Newswire / March 21, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that (i) it has delivered conditional notices of rede...

7 days ago - Accesswire

Bausch Health Announces Launch of Syndication of New Senior Secured Credit Facilities

Transaction is part of a broader refinancing initiative aimed at opportunistically accessing capital markets to address near- and mid-term maturities LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bau...

9 days ago - Accesswire

Bausch Health Announces Launch of Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes

LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has launched an offering (the "Offering") of ...

9 days ago - Accesswire

Bausch Health Announces Next Steps in Financing Initiative with J.P. Morgan

LAVAL, QC / ACCESS Newswire / March 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver bett...

14 days ago - Accesswire

Bausch Health Companies Inc. (BHC) J.P. Morgan Global Leveraged Finance Conference Transcript

Bausch Health Companies Inc. (BHC) J.P. Morgan Global Leveraged Finance Conference Transcript

4 weeks ago - Seeking Alpha

Bausch + Lomb: Solid 2024 Results, But Let's Address The Elephant In The Room

Bausch + Lomb reported solid Q4 and full-year 2024 earnings, with CEO Brent Saunders highlighting positives while avoiding the critical issue of Bausch Health's potential sale of its 88% stake. The co...

5 weeks ago - Seeking Alpha

Bausch Health Q4 Earnings Recap (Reiterating Buy Rating)

Bausch Health reported strong Q4 results with a 6.2% Y/Y revenue increase and positive net income, driving a 10% stock rally. Key growth drivers include Salix, Xifaxan, and Solta, with a focus on long...

5 weeks ago - Seeking Alpha

Bausch Health Companies Inc. (BHC) Q4 2024 Earnings Call Transcript

Bausch Health Companies Inc. (NYSE:BHC) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Conf...

5 weeks ago - Seeking Alpha

Bausch Health Announces Fourth Quarter and Full-Year 2024 Results

Seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1, delivering results at the high-end and/or exceeding 2024 guidance Fourth Quarter Consolidated Reve...

5 weeks ago - Accesswire

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-qua...

5 weeks ago - Business Wire

Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference

LAVAL, QC / ACCESS Newswire / February 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that it will participate in the 2025 J.P. Morgan Global Leveraged Finance Conference...

6 weeks ago - Accesswire

Skincare Devices Market and Competition Analysis 2025-2030, Featuring 42 Major Companies Including Alma Lasers, Bausch Health Companies, Lumenis, Merz Pharma & More

Technological Advancements in Microcurrent and Radiofrequency Devices Propel Market Growth Technological Advancements in Microcurrent and Radiofrequency Devices Propel Market Growth

6 weeks ago - GlobeNewsWire

Bausch Health Announces 2025 Salix Gastrointestinal Health Scholars Program

Bausch Health to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC / ACCESS Newswire / February 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology...

6 weeks ago - Accesswire

Contact lens maker Bausch + Lomb rules out take-private deal

Bausch + Lomb will not be taken private at this time, the contact lens maker said on Thursday.

7 weeks ago - Reuters

Bausch Health Provides Update on Strategic Alternatives

LAVAL, QC / ACCESS Newswire / February 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives throu...

Other symbols: BLCO
7 weeks ago - Accesswire

Bausch + Lomb Provides Update on Potential Sale

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following update on...

7 weeks ago - Business Wire

Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, February 19, 2025. Bausch Health will host a conferen...

2 months ago - Accesswire

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarte...

2 months ago - Business Wire

Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program

LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for...

2 months ago - Accesswire